News

Vertex raises full-year 2026 revenue guidance to $13.1-$13.2 billion as CASGEVY and JOURNAVX show strong sequential growth, while advancing a robust pipeline and strategic Crinetics acquisition.

Vertex Pharmaceuticals (NASDAQ:VRTX) reported second-quarter 2026 revenue growth of 12% year over year to $3.3 billion, driven by continued growth in its cystic fibrosis franchise and rising contributions from newer products CASGEVY and JOURNAVX. Chief Executive Officer and President Reshma Kewalra

Although the revenue and EPS for Vertex (VRTX) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Vertex (VRTX) delivered earnings and revenue surprises of -1.25% and +3.32%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Vertex stock dipped late Monday on a mixed second-quarter report. But the biotech giant raised its sales guidance for the year.

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results this Monday after the bell. Here’s what to look for.

Evaluate the expected performance of Vertex (VRTX) for the quarter ended June 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

VRTX heads into its Q2 earnings release with Trikafta, Alyftrek, Casgevy and Journavx in focus as investors watch product sales and updates on ongoing pipeline studies.

Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Vertex Pharmaceuticals will release its second-quarter earnings next month, and analysts anticipate a single-digit bottom-line growth.

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Vertex Pharmaceuticals' first quarter results reflected balanced growth across its cystic fibrosis franchise and newly launched therapies, with management highlighting commercial momentum in both established and emerging product areas. CEO Reshma Kewalramani pointed to "strong revenue growth as we reach more patients with more products," emphasizing milestone achievements for AlifTrack, KASJEVY, and Gernavix. The company also attributed performance to broader label eligibility and successful int

Vertex's new drugs are gaining momentum as Alyftrek tops $1 billion in sales and Journavx prescriptions accelerate.

Vertex tops Q1 estimates as revenues climb 8% on strong CF drug demand and new product gains. Its pipeline has advanced and its 2026 guidance reaffirmed.

While overall revenue fell just shy of Wall Street forecasts, sales of the gene editing medicine Casgevy and pain drug Journavx missed analyst estimates by double-digit percentages.

Moby summary of Vertex Pharmaceuticals Incorporated's Q1 2026 earnings call

Vertex Pharmaceuticals (NASDAQ:VRTX) reported first-quarter 2026 total revenue of $2.99 billion, up 8% year over year, as growth in its cystic fibrosis (CF) franchise and contributions from newer launches helped drive results. CEO and President Dr. Reshma Kewalramani said the company is “off to a te

Vertex Pharmaceuticals Incorporated is off to a terrific start in 2026, which we see as a year defined by execution. Q1 revenue growth was strong across the portfolio as we reach more patients with more products and delivered total product revenue of $2.99 billion, reflecting 8% growth year over year. Another highlight in Q1 was that products from the new disease areas, namely KASJEVY and GERNAVICS, drove approximately 25% of total product revenue growth.

The headline numbers for Vertex (VRTX) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Vertex (VRTX) delivered earnings and revenue surprises of +5.76% and +0.19%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

In addition to this commercialization focus, research and clinical progress remain paramount. Before I cover R&D highlights for the quarter, I would like to acknowledge our CSO, David Altshuler's retirement a year from now and the planned CSO transition to Mark Bunnage, our current SVP and Global Head of Research.

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results this Monday after the bell. Here’s what investors should know.

In late April 2026, analysts highlighted expectations for higher year-over-year earnings and revenue at CRISPR Therapeutics ahead of its March-quarter report, alongside strong launch metrics for Casgevy, the gene therapy it co-commercializes with Vertex Pharmaceuticals. An interesting angle for investors is how Casgevy’s early commercial uptake and growing treated-patient base may influence perceptions of CRISPR Therapeutics’ broader gene-editing platform and revenue potential. With the...

VRTX heads into Q1 earnings with Trikafta demand, rising Alyftrek sales, and Casgevy and Journavx sales in focus ahead of the May 4 report.

Myriad (MYGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.